Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : Technically solid

09/21/2021 | 04:08am EDT
long trade
Stop-loss triggered
Entry price : 645.11$ | Target : 680.96$ | Stop-loss : 598$ | Potential : 5.56%
Regeneron Pharmaceuticals shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term.
Investors have an opportunity to buy the stock and target the $ 680.96.
Regeneron Pharmaceuticals : Regeneron Pharmaceuticals : Technically solid
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an enterprise value anticipated at 4.36 times the sales for the current fiscal year, the company turns out to be overvalued.

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 14 398 M - -
Net income 2021 7 222 M - -
Net cash 2021 10 057 M - -
P/E ratio 2021 8,35x
Yield 2021 -
Capitalization 57 402 M 57 402 M -
EV / Sales 2021 3,29x
EV / Sales 2022 3,59x
Nbr of Employees 9 635
Free-Float 82,0%
Upcoming event on REGENERON PHARMACEUTICALS
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 552,11 $
Average target price 681,64 $
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS14.28%57 402
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%66 875
BIONTECH SE222.44%63 484
VERTEX PHARMACEUTICALS-21.55%48 101
BEIGENE, LTD.45.52%35 091